Specialist Updates 
Cardiology

At last, a randomised controlled trial on antihypertensives in COVID-19

The study suggests ACE inhibitors and ARBs are safe, although a leading cardiologist suggests this is 'not the last word'
Medicom Staff writer
1
4 September 2020
Save
Please login to bookmark Close

AusDoc brings you the latest news from the European Society of Cardiology Congress 2020.

Patients on common antihypertensives can continue the medication even if hospitalised with COVID-19, according to the first randomised controlled trial to address the issue.

The BRACE-CORONA trial, conducted in Brazil, found there was no mortality difference between patients who continued to take ACE inhibitors or ARBs and those who ceased the medication, the European Society of Cardiology virtual congress (ESC 2020) was told this week.

Although advice, including in Australia, has been that patients should stick with the medication in the absence of contraindication, there’s been concern that ACE-2, the functional receptor for the SARS-CoV-2 virus, might upregulate in patients with COVID-19, worsening symptoms.

Report

Harassment or bullying behavior
Contains mature or sensitive content
Contains misleading or false information
Contains abusive or derogatory content
Content that breaches the privacy of other individuals
Contains spam, fake content or potential malware

Block Member?

Please confirm you want to block this member.

You will no longer be able to:

  • See blocked member's posts
  • Mention this member in posts
  • Message this member
  • Add this member as a connection

Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.

Report

You have already reported this .